Sinomenine hydrochloride improves DSS-induced colitis in mice through inhibition of the Notch signaling pathway

Linxia Xu1, Wei Liu1, Xixiang Huang1

  • 1Department of Gastroenterology, the First Affiliated Hospital of Bengbu Medical University, No. 287, Changhuai Road, Bengbu, Anhui, 233000, China.

BMC Gastroenterology
|December 18, 2024
PubMed
Abstract

Insights

Sinomenine hydrochloride (SH) effectively treats dextran sodium sulfate (DSS)-induced colitis in mice by reducing disease activity and inflammation. This therapeutic effect is linked to the inhibition of the Notch signaling pathway.

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Molecular Biology

Background:

  • Inflammatory bowel disease (IBD), including colitis, is a significant health concern with limited effective treatments.
  • The Notch signaling pathway plays a critical role in regulating immune responses and tissue homeostasis, and its dysregulation is implicated in IBD pathogenesis.

Purpose of the Study:

  • To investigate the therapeutic efficacy of sinomenine hydrochloride (SH) in a mouse model of dextran sodium sulfate (DSS)-induced colitis.
  • To elucidate the impact of SH treatment on the Notch signaling pathway in the colonic tissue of mice with colitis.

Main Methods:

  • Twenty-four mice were allocated into control, DSS-induced colitis model, and two SH-treated groups (low and high dose).
  • Disease activity index (DAI), colonic mucosal injury, and histopathological scores were assessed.
  • Expression levels of Notch signaling pathway components (Notch1, NICD1, Jagged1, Hes1) and pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) were quantified.

Main Results:

  • SH treatment significantly ameliorated colitis symptoms, evidenced by reduced DAI scores and histopathological injury.
  • SH administration led to a significant downregulation of Notch1, NICD1, Jagged1, and Hes1 protein expression in the colon.
  • Treatment with SH markedly decreased serum levels of pro-inflammatory cytokines, including TNF-α, IL-1β, and IL-6.

Conclusions:

  • Sinomenine hydrochloride demonstrates significant therapeutic potential for DSS-induced colitis in mice.
  • The anti-colitis effects of SH are associated with the inhibition of Notch signaling pathway overactivation.
  • SH may represent a novel therapeutic agent for managing inflammatory bowel diseases.

Related Concept Videos

Role Of Notch Signalling In Intestinal Stem Cell Renewal01:12

Role Of Notch Signalling In Intestinal Stem Cell Renewal

Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.1K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
147